China · Delayed Price · Currency is CNY Kexing Biopharm Statistics
Total Valuation
Kexing Biopharm has a market cap or net worth of CNY 3.18 billion. The enterprise value is 4.02 billion.
| Market Cap | 3.18B |
| Enterprise Value | 4.02B |
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jun 15, 2026 |
Share Statistics
Kexing Biopharm has 198.59 million shares outstanding. The number of shares has decreased by -2.16% in one year.
| Current Share Class | 198.59M |
| Shares Outstanding | 198.59M |
| Shares Change (YoY) | -2.16% |
| Shares Change (QoQ) | +6.54% |
| Owned by Insiders (%) | 51.54% |
| Owned by Institutions (%) | 11.91% |
| Float | 96.23M |
Valuation Ratios
The trailing PE ratio is 45.08 and the forward PE ratio is 25.81.
| PE Ratio | 45.08 |
| Forward PE | 25.81 |
| PS Ratio | 2.44 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 31.86 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 57.11 |
| EV / Sales | 3.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.87.
| Current Ratio | 1.37 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.01 |
Financial Efficiency
Return on equity (ROE) is 3.91% and return on invested capital (ROIC) is -5.06%.
| Return on Equity (ROE) | 3.91% |
| Return on Assets (ROA) | -2.72% |
| Return on Invested Capital (ROIC) | -5.06% |
| Return on Capital Employed (ROCE) | -6.04% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | 1.17M |
| Profits Per Employee | 63,447 |
| Employee Count | 1,109 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 3.87 |
Taxes
In the past 12 months, Kexing Biopharm has paid 10.90 million in taxes.
| Income Tax | 10.90M |
| Effective Tax Rate | 13.90% |
Stock Price Statistics
The stock price has decreased by -58.84% in the last 52 weeks. The beta is 0.58, so Kexing Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -58.84% |
| 50-Day Moving Average | 20.77 |
| 200-Day Moving Average | 24.50 |
| Relative Strength Index (RSI) | 32.67 |
| Average Volume (20 Days) | 6,709,172 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kexing Biopharm had revenue of CNY 1.30 billion and earned 70.36 million in profits. Earnings per share was 0.35.
| Revenue | 1.30B |
| Gross Profit | 717.45M |
| Operating Income | -154.96M |
| Pretax Income | 78.40M |
| Net Income | 70.36M |
| EBITDA | -52.86M |
| EBIT | -154.96M |
| Earnings Per Share (EPS) | 0.35 |
Balance Sheet
The company has 669.60 million in cash and 1.51 billion in debt, with a net cash position of -841.86 million or -4.24 per share.
| Cash & Cash Equivalents | 669.60M |
| Total Debt | 1.51B |
| Net Cash | -841.86M |
| Net Cash Per Share | -4.24 |
| Equity (Book Value) | 1.74B |
| Book Value Per Share | 8.40 |
| Working Capital | 418.39M |
Cash Flow
In the last 12 months, operating cash flow was 99.74 million and capital expenditures -101.17 million, giving a free cash flow of -1.43 million.
| Operating Cash Flow | 99.74M |
| Capital Expenditures | -101.17M |
| Depreciation & Amortization | 102.10M |
| Net Borrowing | 80.70M |
| Free Cash Flow | -1.43M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 55.18%, with operating and profit margins of -11.92% and 5.41%.
| Gross Margin | 55.18% |
| Operating Margin | -11.92% |
| Pretax Margin | 6.03% |
| Profit Margin | 5.41% |
| EBITDA Margin | -4.07% |
| EBIT Margin | -11.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 1.56%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 1.56% |
| Dividend Growth (YoY) | 212.50% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 130.75% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.16% |
| Shareholder Yield | 3.72% |
| Earnings Yield | 2.22% |
| FCF Yield | -0.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |